Ciclesonide is an inhaled corticosteroid used to treat asthma and allergic rhinitis, but it works differently from most steroids in its class. Rather than arriving in the lungs as an active drug, ciclesonide is a prodrug, essentially inert until enzymes in the airways convert it into its active form. That design gives it a distinctive safety profile that has made it a go-to option when side effects from other inhaled steroids become a concern, and it has also drawn attention from researchers investigating whether it can do things corticosteroids were never designed for.
How the Prodrug Design Works
Most inhaled corticosteroids are already pharmacologically active when you inhale them. Whatever lands on your tongue, throat, or gets swallowed is biologically active drug sitting in places where it can cause local side effects or be absorbed into your bloodstream. Ciclesonide takes a different approach. The molecule you inhale has very little ability to bind to the glucocorticoid receptor on its own. It only becomes potent after enzymes called carboxylesterases in your airway lining clip off part of the molecule, turning it into the active metabolite known as des-CIC.
This conversion happens quickly in lung tissue. In human bronchial epithelial cells, roughly 30% of ciclesonide converts to des-CIC within four hours, with nearly complete conversion by 24 hours.1PubMed. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue When researchers examined actual human lung tissue after inhalation, the active metabolite was already the dominant form at the earliest time point measured, about two hours post-dose.2European Respiratory Journal. Deposition and metabolism of inhaled ciclesonide in the human lung The result is that most of the anti-inflammatory firepower gets generated right where it is needed, in the airways, rather than throughout the body.
Once des-CIC is formed, it binds to the glucocorticoid receptor with an affinity comparable to fluticasone propionate, one of the most widely used inhaled steroids.3The Journal of Pharmacology and Experimental Therapeutics. Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma So the drug is not weaker than its competitors once activated. The advantage lies in where the activation happens and what happens to any drug that ends up in the wrong place.
Getting the Drug Where It Needs to Go
Inhaler technology matters a lot for how much drug actually reaches your lungs versus how much sticks to your mouth and throat. Ciclesonide is formulated as a solution in a hydrofluoroalkane (HFA) metered-dose inhaler, and the resulting aerosol produces very small particles. In imaging studies using radiolabeled ciclesonide, about 52% of the delivered dose deposited in the lungs, with only about 33% landing in the mouth and throat.4PubMed. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma Three-dimensional imaging in that same study showed the drug concentrating in the peripheral lung regions, where the small airways and alveoli sit. That deep penetration pattern is relevant because inflammation in the small airways contributes to asthma symptoms but is harder to reach with larger-particle inhalers.5PubMed Central. From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids
Once des-CIC forms in the airway tissue, it undergoes another trick: it gets tagged with fatty acids inside cells, creating fat-soluble conjugates that act as a local reservoir. These conjugates are broken down slowly, releasing active drug over time. Des-CIC-oleate, one of these conjugates, is roughly five times more fat-soluble than the equivalent budesonide conjugate, which may mean it stays embedded in airway tissue longer.6PubMed Central. Metabolism of ciclesonide in the upper and lower airways: review of available data This depot effect is part of why ciclesonide can be dosed once daily for many patients.
Effectiveness in Asthma
Ciclesonide is approved for maintenance treatment of persistent asthma. In clinical trials, it improves lung function, reduces symptoms, and lowers exacerbation rates. A head-to-head trial comparing low-dose ciclesonide (80 micrograms once daily) with fluticasone propionate (100 micrograms twice daily) in about 480 patients with mild-to-moderate asthma found that ciclesonide was non-inferior to fluticasone for improving lung function over 24 weeks.7PubMed Central. From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids That is a meaningful comparison because fluticasone propionate is one of the most commonly prescribed inhaled steroids worldwide, and ciclesonide achieved similar results with once-daily dosing instead of twice-daily.
For people with more severe asthma, higher doses of ciclesonide hold up as well. In a trial of patients with severe persistent asthma, both 160 and 640 microgram daily doses significantly improved lung function, with the higher dose offering a lower exacerbation rate (about 7% versus 13% for the lower dose) and a longer time to first exacerbation.8PubMed. Randomized comparison of ciclesonide 160 and 640 microg/day in severe asthma A separate 12-week trial in severe asthma patients confirmed significant improvements in peak flow and symptom scores at both 320 and 640 microgram twice-daily doses.9PubMed. Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-up
None of this means ciclesonide is dramatically more effective than other inhaled steroids at controlling asthma. The evidence shows it performs in the same league. Where it distinguishes itself is the side-effect profile.
Why the Safety Profile Stands Out
Two concerns dominate discussions about long-term inhaled corticosteroid use: local side effects in the mouth and throat (thrush, hoarseness, sore throat) and systemic effects from drug absorbed into the bloodstream (cortisol suppression, bone thinning, and in children, growth slowing). Ciclesonide’s design addresses both.
Because the parent compound is largely inactive, the portion that deposits in the mouth and throat does very little. Oropharyngeal side effects with ciclesonide have been reported at rates comparable to placebo in clinical trials.10PubMed. Ciclesonide: a closer look at its systemic and oropharyngeal safety profile For anyone who has dealt with oral thrush from fluticasone or beclomethasone, this is a meaningful practical difference. Mouth rinsing after inhalation is still generally recommended, but the risk of developing candidiasis is considerably lower.
On the systemic side, both ciclesonide and its active metabolite are about 99% bound to proteins in the bloodstream, which limits how much free drug is available to affect organs elsewhere in the body.11European Respiratory Journal. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma The liver also clears ciclesonide rapidly, so any swallowed drug has low oral bioavailability.12PubMed. Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids
The clearest evidence for the systemic safety advantage comes from head-to-head cortisol suppression studies. In one trial, fluticasone propionate at 500 and 1,000 micrograms per day significantly suppressed cortisol secretion compared to placebo, while neither 320 nor 640 micrograms per day of ciclesonide produced significant suppression.13European Respiratory Journal. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma A separate study measuring cortisol response to stimulation testing and 24-hour urinary cortisol confirmed the same pattern: ciclesonide groups looked like placebo, while the fluticasone group showed significant reductions.14PubMed. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma Across the studied dose range, up to 1,280 micrograms per day, ciclesonide has not been reported to cause significant adrenal suppression.15PubMed. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate
Use in Children
Growth suppression is one of the biggest worries parents have about putting a child on a daily inhaled steroid, and it is a legitimate concern with some drugs in this class. A year-long growth velocity study in children found that ciclesonide at both 40 and 160 micrograms daily was non-inferior to placebo for growth rate. The difference from placebo was just 0.02 centimeters per year at the lower dose and 0.15 centimeters per year at the higher dose, both effectively negligible.16PubMed. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma The RAINBOW study, a trial testing three ciclesonide doses in children, found no between-group differences in body height or urinary cortisol compared with placebo, while all three doses improved asthma control and lung function.17PubMed. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study
That said, a Cochrane systematic review comparing ciclesonide with budesonide and fluticasone in children concluded that the evidence is not strong enough to say definitively whether ciclesonide is better, worse, or the same as those alternatives for pediatric asthma outcomes and side effects.18Cochrane Database of Systematic Reviews. Ciclesonide versus other inhaled corticosteroids for chronic asthma in children The individual trials are encouraging, but there simply have not been enough large head-to-head comparisons to draw firm conclusions about superiority in children. In practice, ciclesonide tends to be considered when a child is experiencing side effects from another inhaled steroid or when there is particular concern about systemic effects.
The Nasal Spray for Allergic Rhinitis
Ciclesonide is also available as a nasal spray (brand name Omnaris or Zetonna, depending on formulation) for seasonal and perennial allergic rhinitis. The same prodrug logic applies: the spray is activated by enzymes in the nasal mucosa, which limits local irritation and systemic absorption.19PubMed Central. Intranasal ciclesonide for allergic rhinitis In a long-term trial running more than 52 weeks, intranasal ciclesonide achieved significantly better nasal symptom control than placebo in adults and adolescents with perennial allergic rhinitis.20PubMed. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis
One practical advantage some people notice with the nasal formulation is less of the unpleasant taste or nasal dryness that can accompany other nasal steroid sprays. This is partly because the inactive parent compound has no local pharmacological effect on the nasal lining where it first lands, and partly because the formulation itself does not contain alcohol, which is a common irritant in other nasal sprays.
Adherence and the Once-Daily Advantage
The best asthma controller medication in the world does nothing if it stays in the drawer. Adherence is a persistent problem with inhaled steroids, and once-daily dosing, lower side effects, and patient comfort all influence whether someone actually keeps using their inhaler. A randomized trial comparing ciclesonide with budesonide during a step-down from higher-dose therapy found a striking difference: 76% of ciclesonide patients maintained treatment adherence compared with 59% in the budesonide group. Among those who dropped out, poor asthma control was the reason far more often in the budesonide group (27% of all budesonide patients versus 5% of ciclesonide patients). Patient satisfaction was also higher with ciclesonide, with 70% of patients reporting they were at least satisfied compared with about 48% in the budesonide group.21npj Primary Care Respiratory Medicine. Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: a randomised parallel-group study
These numbers likely reflect a combination of factors: once-daily dosing is easier to remember than twice-daily, fewer mouth and throat side effects mean fewer reasons to stop, and the perception of tolerability matters. If your inhaler leaves a bad taste or gives you a hoarse voice, you are more likely to skip doses even if you know you should not.
The COVID-19 Chapter
Early in the pandemic, a Japanese research group screened a library of existing drugs for activity against coronaviruses and found that ciclesonide suppressed replication of SARS-CoV-2 in lab cell cultures. The effect appeared to be specific: ciclesonide blocked coronavirus replication but did not suppress respiratory syncytial virus or influenza virus in the same system.22PubMed Central. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells The researchers identified the target as a component of the viral replication machinery, which was an unusual finding for a corticosteroid and suggested the antiviral effect was separate from ciclesonide’s anti-inflammatory action.
This lab work led to several clinical trials with mixed results. A small open-label phase 2 trial in South Korea found that the SARS-CoV-2 eradication rate at day 14 was significantly higher in patients inhaling ciclesonide compared with standard care, and the clinical failure rate was lower.23PubMed Central. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial A larger randomized, placebo-controlled trial found that ciclesonide reduced COVID-related emergency department visits and hospitalizations by day 30 (about 1% in the ciclesonide group versus 5% in the placebo group), though no other secondary outcomes reached statistical significance.24JAMA Internal Medicine. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial
However, a separate randomized trial using both inhaled and intranasal ciclesonide found no significant difference in symptom resolution by day 7 between the ciclesonide and control groups.25The BMJ. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial The inconsistency across trials, combined with differences in study design, timing of treatment, and endpoints measured, means the antiviral story remains interesting but unresolved. Ciclesonide is not approved or widely recommended for COVID-19 treatment. The episode illustrates how a drug can show genuine biological activity against a pathogen in the lab without that translating cleanly into clinical benefit.
Eosinophilic Esophagitis
One of the more intriguing off-label uses for ciclesonide is in eosinophilic esophagitis (EoE), a chronic inflammatory condition of the swallowing tube. EoE is driven by eosinophils, a type of white blood cell, accumulating in the esophageal lining and causing symptoms like difficulty swallowing, food impaction, and chest pain. Swallowed topical corticosteroids, principally budesonide and fluticasone, are a mainstay of treatment. Ciclesonide is being explored as an alternative because its low systemic absorption could offer the local anti-inflammatory effect with even less whole-body steroid exposure.
A retrospective study of 81 patients treated with ciclesonide for EoE found significant improvements across the board: reduced difficulty swallowing, lower abdominal pain, decreased vomiting, and improvements in the endoscopic appearance of the esophagus. Peak eosinophil counts dropped from 48 to 23 per high-power field, and about 53% of patients achieved histologic remission.26PubMed. Ciclesonide Impacts Clinicopathological Features of Eosinophilic Esophagitis The evidence is still early, and published trials are small, but the results have been encouraging enough to keep ciclesonide in the conversation as a treatment option, especially for patients who do not respond well to budesonide or fluticasone.27Inflammatory Intestinal Diseases. Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs
Cost and Availability Considerations
Ciclesonide’s main practical drawback is price. In many markets it costs more than generic budesonide or fluticasone propionate, which are available in multiple inexpensive formulations. A cost-utility analysis of inhaled steroids for pediatric asthma in a developing-country context found that fluticasone dominated both budesonide and ciclesonide, meaning it produced slightly better quality-adjusted outcomes at lower cost.28PubMed. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma That kind of analysis does not capture the value ciclesonide provides for the subset of patients who experience intolerable side effects on cheaper alternatives, but it does explain why ciclesonide is rarely a first-line recommendation in resource-constrained settings or in formularies that prioritize generics.
In the United States, ciclesonide for asthma (brand name Alvesco) and its nasal formulations have been available for well over a decade. Generic versions have become available in some markets, which has begun to bring costs down. Insurance coverage varies, and prior authorization requirements are common; your insurer may require documentation that you have tried and failed another inhaled steroid before covering ciclesonide. If you are prescribed ciclesonide and find the out-of-pocket cost high, it is worth asking your pharmacist about manufacturer coupons or comparing pricing across pharmacies, as the cash price can vary substantially.
When Clinicians Reach for Ciclesonide
Because its efficacy in asthma is broadly similar to other inhaled steroids, ciclesonide tends to fill a specific niche rather than being the default first prescription. The most common scenarios where it gets chosen include patients who develop oral thrush or hoarseness on fluticasone or budesonide, children whose parents are concerned about growth effects, patients who prefer or benefit from once-daily dosing, and people who need higher steroid doses where the risk of cortisol suppression from other agents becomes more of a concern. It is also sometimes tried in patients with small-airway disease that is not well controlled on other inhalers, given its small particle size and deep lung penetration.
For allergic rhinitis, ciclesonide nasal spray occupies a similar niche: it is effective and well tolerated, but usually considered after other nasal steroids, often because of cost. People who find other nasal sprays irritating or who dislike the aftertaste some sprays leave may find ciclesonide more comfortable to use long-term, which ultimately matters for a condition where consistent daily use is the whole point of treatment.